Cagrilintide 10mgResearch Peptide

Overview

Cagrilintide is a long-acting amylin analog investigated in published research for its role in metabolic regulation, satiety signalling and the control of gastric emptying in animal and clinical study models. It is engineered for extended receptor activity, with a reported half-life of roughly one week that has supported once-weekly dosing schedules in the published trial literature. This vial contains 10mg of cagrilintide as a lyophilised powder for reconstitution with sterile diluent in the laboratory.

What is Cagrilintide?

Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells that participates in the regulation of satiety and post-meal glucose handling. Cagrilintide is a synthetic, acylated amylin analog developed to resist rapid clearance, extending activity from the roughly 50-minute half-life of the first-generation analog pramlintide to approximately 180 hours. In the published literature it is described as an agonist at both the amylin and calcitonin receptors. Cagrilintide is best known in the research literature as the amylin component of the investigational combination studied alongside semaglutide, where the two peptides have been co-administered to probe complementary signalling pathways in metabolic research.

Mechanism of Action

Published research describes amylin analogs such as cagrilintide as acting on satiety circuits in the area postrema and hypothalamus, slowing gastric emptying and modulating glucagon signalling. The dual amylin and calcitonin receptor activity reported for cagrilintide is an active area of investigation, and researchers have examined how these pathways interact with incretin signalling in preclinical and clinical study models. The precise molecular mechanisms and downstream effects remain an active area of investigation in the published literature.

Published Research

Published research on cagrilintide has spanned preclinical models and human clinical trials investigating metabolic endpoints. Areas of investigation have included:

Amylin and calcitonin receptor signalling

Satiety and food-intake research in animal and clinical models

Gastric emptying and post-prandial glucose handling

Combination research alongside GLP-1 receptor agonists

Once-weekly pharmacokinetic profiling

Cagrilintide is not approved by the TGA for any therapeutic indication.

Quality and Verification

Every batch ships with a batch-specific Certificate of Analysis documenting purity by HPLC (>=99%) and mass spectrometry confirmation of peptide identity. The COA is published online on this product page rather than included in the box. The vial is shipped lyophilised to preserve stability during transit and should be stored at -20C prior to reconstitution and 2-8C after reconstitution in the laboratory.

Further Reading

For background on handling lyophilised research peptides, see our reconstitution calculator.

Disclaimer

For research use only. Not for human consumption. The information provided is for educational and research purposes only. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult published peer-reviewed literature before designing research protocols.